[Has interleukin 2 modified the outcome of metastatic kidney cancer?].
Immunotherapy offers a limited but definite hope in the course of metastatic renal cancer. Interferon alpha gives 2% complete remissions and 14% partial responses. Interleukin 2 achieves 5-10% complete remissions and 20% partial responses. The combination of the two agents does not really improve the results. In contrast, culture of TIL cells in the presence of IL-2 provides encouraging results.